MINAPHARM Pharmaceuticals (EGX:MIPH)
Egypt · Delayed Price · Currency is EGP 742.36
-5.74 (-0.77%)
At close: Oct 22, 2026
MINAPHARM Pharmaceuticals Income Statement
Financials in millions EGP. Fiscal year is January - December.
Millions EGP. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 7,195 | 6,438 | 5,600 | 3,892 | 3,621 | 3,005 | |
Revenue Growth | 4.71% | 14.97% | 43.87% | 7.50% | 20.47% | 27.29% |
Cost of Revenue | 4,881 | 4,138 | 3,668 | 2,640 | 2,124 | 1,820 |
Gross Profit | 2,314 | 2,300 | 1,932 | 1,252 | 1,496 | 1,185 |
Selling, General & Admin | 1,072 | 1,039 | 824.23 | 718.51 | 474.95 | 392.79 |
Research & Development | 189.07 | 224.72 | 131.26 | 151.27 | 59.35 | 45.84 |
Operating Expenses | 1,327 | 1,282 | 998.11 | 876.91 | 531.63 | 431.37 |
Operating Income | 986.89 | 1,019 | 933.85 | 374.66 | 964.74 | 753.96 |
Interest Expense | -684.68 | -748.64 | -593.68 | -254.46 | -62.17 | -48.84 |
Interest & Investment Income | 76.94 | 63.88 | 57.23 | 14.06 | 9.55 | 5.08 |
Currency Exchange Gain (Loss) | 247.79 | -21.14 | - | -37.3 | 37.52 | -1.76 |
Other Non Operating Income (Expenses) | -160.34 | -98.57 | -117.27 | -63.76 | -69.3 | -40.66 |
EBT Excluding Unusual Items | 466.6 | 214.14 | 280.12 | 33.2 | 880.34 | 667.79 |
Gain (Loss) on Sale of Assets | -0.16 | -0.15 | -0.45 | -0.17 | - | 0.46 |
Asset Writedown | -0.93 | - | - | - | - | - |
Pretax Income | 466 | 213.99 | 279.67 | 33.03 | 880.34 | 668.25 |
Income Tax Expense | 98.67 | 166.79 | 118.57 | 10.67 | 249.44 | 193.38 |
Earnings From Continuing Operations | 367.33 | 47.2 | 161.11 | 22.36 | 630.89 | 474.87 |
Minority Interest in Earnings | -4.43 | -6.98 | -4.04 | -54.35 | -18.23 | -8.46 |
Net Income | 362.9 | 40.22 | 157.07 | -31.99 | 612.66 | 466.41 |
Preferred Dividends & Other Adjustments | 39.03 | 33.6 | 28.85 | 23.4 | 22.75 | 18.7 |
Net Income to Common | 323.88 | 6.62 | 128.22 | -55.39 | 589.91 | 447.71 |
Net Income Growth | - | -94.84% | - | - | 31.76% | 56.95% |
Shares Outstanding (Basic) | 11 | 11 | 11 | 11 | 11 | 12 |
Shares Outstanding (Diluted) | 11 | 11 | 11 | 11 | 11 | 12 |
Shares Change | - | - | - | -3.57% | -6.67% | - |
EPS (Basic) | 29.27 | 0.60 | 11.59 | -5.01 | 51.41 | 36.42 |
EPS (Diluted) | 29.27 | 0.60 | 11.59 | -5.01 | 51.41 | 36.42 |
EPS Growth | - | -94.84% | - | - | 41.17% | 56.95% |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -1,231 | -322.99 | -697.45 | -1,292 | -598.45 | -180.6 |
Free Cash Flow Per Share | -111.25 | -29.19 | -63.04 | -116.81 | -52.16 | -14.69 |
Dividend Per Share | - | - | 2.500 | 1.650 | 2.800 | 2.922 |
Dividend Growth | - | - | 51.52% | -41.07% | -4.17% | 8.21% |
Gross Margin | 32.16% | 35.73% | 34.50% | 32.16% | 41.33% | 39.44% |
Operating Margin | 13.72% | 15.82% | 16.68% | 9.63% | 26.65% | 25.09% |
Profit Margin | 4.50% | 0.10% | 2.29% | -1.42% | 16.29% | 14.90% |
Free Cash Flow Margin | -17.11% | -5.02% | -12.46% | -33.21% | -16.53% | -6.01% |
EBITDA | 1,361 | 1,348 | 1,172 | 536.04 | 1,086 | 835.91 |
EBITDA Margin | 18.92% | 20.94% | 20.93% | 13.77% | 29.99% | 27.81% |
D&A For EBITDA | 374.44 | 329.53 | 238.38 | 161.38 | 121.14 | 81.95 |
EBIT | 986.89 | 1,019 | 933.85 | 374.66 | 964.74 | 753.96 |
EBIT Margin | 13.72% | 15.82% | 16.68% | 9.63% | 26.65% | 25.09% |
Effective Tax Rate | 21.17% | 77.94% | 42.39% | 32.29% | 28.34% | 28.94% |
Advertising Expenses | - | 25.66 | 13.23 | - | 8.4 | 15.38 |